NEW YORK (TheStreet) -- Valeant Pharmaceuticals and Allergan are higher on Monday thanks to Valeant reporting good earnings and saying it is considering raising its bid for Allergan. Jim Cramer, the co-manager of the Action Alerts PLUS portfolio, said he's "never seen a situation where there are so many winners." On CNBC's "Cramer's Stop Trading" segment, he noted Valeant Pharmaceuticals beat revenue and earnings estimates. He said he's "not been a fan" of Valeant but admittted the company continues to deliver solid results for investors.
